2015 Annual Meeting | Advances in ALS and Other Motor Neuron Diseases
| 01:00 PM - 01:05 PM |
Introduction
|
|
| 01:00 PM - 05:00 PM | Abstract |
001 - ALS and Military Occupation: A Population-Based Case-Control Study in the Danish Registries
Ryan M. Seals |
| 01:00 PM - 05:00 PM | Abstract |
002 - Head Injury Does Not Alter Disease Progression or Neuropathological Outcomes in ALS
Christina N. Fournier, MD, MSc |
| 01:00 PM - 05:00 PM | Abstract |
003 - Threshold tracking TMS: A novel diagnostic technique for Amyotrophic Lateral Sclerosis
Nimeshan Geevasinga, MD, PhD |
| 01:00 PM - 05:00 PM | Abstract |
004 - Advance directives and palliative care in ALS patients. The Piedmont and Valle d’Aosta register experience
Andrea Calvo, MD, PhD, FAAN |
| 01:00 PM - 05:00 PM | Abstract |
005 - The ALSUntangled Table of Evidence
Richard S. Bedlack, MD, PhD, FAAN |
| 01:00 PM - 05:00 PM | Abstract |
006 - Transplantation of an iPSC-derived CD15+CXCR4+VLA4+ neural stem cell subpopulation as a new therapy for ALS.
|
| 01:00 PM - 05:00 PM | Abstract |
007 - A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Six-Month Clinical Trial Followed by an Open-Label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of the Phosphodiesterase Type 4 (PDE4) Inhibitor Ibudilast (MN-166) in Subjects with Amyotrophic Lateral Sclerosis (ALS) - STEP-IBUDILAST-ALS-DB-OLE-1
Benjamin R. Brooks, MD, FAAN |
| 01:00 PM - 05:00 PM | Abstract |
008 - Transthyretin as Potential Biomarker for C9ORF72-related Diseases
Marka M. Van Blitterswijk, MD, PhD |
| 01:00 PM - 05:00 PM | Abstract |
009 - The ALS/FTD C9ORF72 hexanucleotide expansion disrupts nucleocytoplasmic transport
Thomas E. Lloyd, MD, PhD |
| 01:00 PM - 05:00 PM | Abstract |
010 - Large-scale exome sequencing in ALS identifies new risk genes and pathways
Matthew Harms, MD |
| 01:00 PM - 05:00 PM | Abstract |
011 - ATXN2 PolyQ Intermediate Repeat Modifies ALS Phenotype and Survival
Adriano Chio, MD, FAAN |
| 01:00 PM - 05:00 PM | Abstract |
012 - Grey And White Matter Mri Signatures Of The Frontotemporal Lobar Degeneration Continuum
Massimo Filippi, MD, FAAN |
| 01:00 PM - 05:00 PM | Abstract |
013 - Longitudinal assessment of frontal cognitive impairment in patients with motor neuron disease
Pilar Maria Ferraro, PhD |
| 01:05 PM - 01:35 PM |
ALS Clinical Trials: What Have We Learned
Merit E. Cudkowicz, MD, MSC, FAAN |
|
| 01:35 PM - 01:40 PM |
Transplantation of an iPSC-derived CD15+CXCR4+VLA4+ Neural Stem Cell Subpopulation as a New Therapy for ALS
|
|
| 01:40 PM - 01:45 PM |
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Six-Month Clinical Trial Followed by an Open-Label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of the Phosphodiesterase Type 4 (PDE4) Inhibitor
Benjamin R. Brooks, MD, FAAN |
|
| 01:45 PM - 01:55 PM |
Questions and Answers
|
|
| 01:55 PM - 02:25 PM |
Advances in Our Understanding of the Basic Science of ALS
Robert H. Brown, Jr., MD, DPhil |
|
| 02:25 PM - 02:30 PM |
Transthyretin as Potential Biomarker for C9ORF72-related Diseases
Marka M. Van Blitterswijk, MD, PhD |
|
| 02:30 PM - 02:35 PM |
The ALS/FTD C9ORF72 Hexanucleotide Expansion Disrupts Nucleocytoplasmic Transport
Thomas E. Lloyd, MD, PhD |
|
| 02:35 PM - 02:45 PM |
Question and Answers
|
|
| 02:45 PM - 02:55 PM |
Break
|
|
| 02:55 PM - 03:25 PM |
Taking the Genetics of ALS to the Next Step
Orla Hardiman, MD, FRCPI, FAAN |
|
| 03:25 PM - 03:30 PM |
Large-scale Exome Sequencing in ALS Identifies New Risk Genes and Pathways
Matthew Harms, MD |
|
| 03:30 PM - 03:35 PM |
ATXN2 PolyQ Intermediate Repeat Modifies ALS Phenotype and Survival
Adriano Chio, MD, FAAN |
|
| 03:35 PM - 03:45 PM |
Questions and Answers
|
|
| 03:45 PM - 04:15 PM |
The Overlap of ALS and Frontotemporal Dementia
Michael J. Strong, MD, FAAN |
|
| 04:15 PM - 04:20 PM |
Grey and White Matter MRI Signatures of the Frontotemporal Lobar Degeneration Continuum
Massimo Filippi, MD, FAAN |
|
| 04:20 PM - 04:25 PM |
Longitudinal Assessment of Frontal Cognitive Impairment in Patients with Motor Neuron Disease
Pilar Maria Ferraro, PhD |
|
| 04:25 PM - 04:35 PM |
Questions and Answers
|
|
| 04:35 PM - 05:00 PM |
Guided Poster Rounds
|
| Catherine Lomen-Hoerth, MD, PhD, FAAN | Dr. Lomen-Hoerth has nothing to disclose. |
| Tahseen Mozaffar, MD, FAAN | Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Mozaffar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Mozaffar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amicus. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Grifols. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Astellas Gene Therapy. Dr. Mozaffar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bayer. Dr. Mozaffar has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Applied Therapeutics. The institution of Dr. Mozaffar has received research support from NIH. The institution of Dr. Mozaffar has received research support from Muscular Dystrophy Association. The institution of Dr. Mozaffar has received research support from Sanofi. The institution of Dr. Mozaffar has received research support from Argenx. The institution of Dr. Mozaffar has received research support from Amicus Therapeutics. The institution of Dr. Mozaffar has received research support from Astellas Gene Therpay. The institution of Dr. Mozaffar has received research support from Cartesian. The institution of Dr. Mozaffar has received research support from Cabaletta. Dr. Mozaffar has received personal compensation in the range of $500-$4,999 for serving as a Study Section Member with NIH. |
| Merit E. Cudkowicz, MD, MSC, FAAN | Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for biogen. Dr. Cudkowicz has received personal compensation in the range of $0-$499 for serving as a Consultant for cytokinetics. Dr. Cudkowicz has received personal compensation in the range of $0-$499 for serving as a Consultant for immunitypharm. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for transposon. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Quralis. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Regeneron. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for vectorY. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for inflectis. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for novartis. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ono. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for otsuka. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for coya. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ac immune. Dr. Cudkowicz has received personal compensation in the range of $0-$499 for serving as a Consultant for pontifax. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Inflectis. Dr. Cudkowicz has received personal compensation in the range of $0-$499 for serving as a Consultant for ab science. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for aclipse. Dr. Cudkowicz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Locust Walk. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pasithea. Dr. Cudkowicz has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Praxis Precision Medicine. Dr. Cudkowicz has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Annals of Neurology . The institution of Dr. Cudkowicz has received research support from NINDS. The institution of Dr. Cudkowicz has received research support from ALSFAC. The institution of Dr. Cudkowicz has received research support from UCB ra. The institution of Dr. Cudkowicz has received research support from Biohaven. The institution of Dr. Cudkowicz has received research support from Clene nanomedicine. The institution of Dr. Cudkowicz has received research support from prilenia. The institution of Dr. Cudkowicz has received research support from ALS one. The institution of Dr. Cudkowicz has received research support from Seelos. The institution of Dr. Cudkowicz has received research support from Calico. The institution of Dr. Cudkowicz has received research support from denali. The institution of Dr. Cudkowicz has received research support from ITB. The institution of Dr. Cudkowicz has received research support from PharmAust. The institution of Dr. Cudkowicz has received research support from woolsley. Dr. Cudkowicz has received research support from lilly. The institution of Dr. Cudkowicz has received research support from J& J. Dr. Cudkowicz has received publishing royalties from a publication relating to health care. |
| Michael J. Strong, MD, FAAN | No disclosure on file |
| Robert H. Brown, Jr., MD, DPhil | Dr. Brown has received personal compensation for serving as an employee of ApicBio. Dr. Brown has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for ApicBio. Dr. Brown has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Warren Alpert Foundation. Dr. Brown has stock in ApicBio. Dr. Brown has stock in Amylx. Dr. Brown has stock in Imstar. The institution of Dr. Brown has received research support from Angel Fund for ALS Research. The institution of Dr. Brown has received research support from ALS Association. The institution of Dr. Brown has received research support from ALSOne. The institution of Dr. Brown has received research support from NINDS. The institution of Dr. Brown has received research support from ALS Finding A Cure. Dr. Brown has received publishing royalties from a publication relating to health care. |
| Orla Hardiman, MD, FRCPI, FAAN | Dr. Hardiman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Wave Pharmaceuticals. Dr. Hardiman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cytokinetics . Dr. Hardiman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Hardiman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Taylor and Francis. The institution of Dr. Hardiman has received research support from Science Foundation Ireland. The institution of Dr. Hardiman has received research support from HRB. |
| Thomas E. Lloyd, MD, PhD | Dr. Lloyd has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. |
| No disclosure on file | |
| Pilar Maria Ferraro, PhD | No disclosure on file |
| Massimo Filippi, MD, FAAN | Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. |
| Matthew Harms, MD | Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Harms has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Muscular Dystrophy Association. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Invitae. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Variant Bio. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for uniQure. Dr. Harms has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Littlepage Booth. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for O'Connor First. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Searcy Denney. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Ford, Parshall & Baker LLC . The institution of Dr. Harms has received research support from ALS Association. The institution of Dr. Harms has received research support from Ionis. The institution of Dr. Harms has received research support from ALS Finding a Cure. The institution of Dr. Harms has received research support from Target ALS. |
| Adriano Chio, MD, FAAN | Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cytokinetics. Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi. Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Chio has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Corcept. |
| Benjamin R. Brooks, MD, FAAN | Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Mitsubishi Tanabe Pharma America. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medicinova. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB Science. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Mitsubishi Tanabe Pharma America. The institution of Dr. Brooks has received research support from Mitsubishi TanabePharma America. Dr. Brooks has received personal compensation in the range of $0-$499 for serving as a Member Annual Surveillance Committee CDC National ALS Registry with Center for Disease Control Agency Toxic Substances Disease Registry. Dr. Brooks has a non-compensated relationship as a Member ALS Quality Measures Subcommittee with 好色先生 that is relevant to AAN interests or activities. |
| Marka M. Van Blitterswijk, MD, PhD | No disclosure on file |
| Stefania Corti, MD, PhD | Dr. Corti has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Corti has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Corti has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. |
| David S. Knopman, MD, FAAN | Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH. |
| Andrea Calvo, MD, PhD, FAAN | Dr. Calvo has nothing to disclose. |
| Dennis W. Dickson, MD | Dr. Dickson has nothing to disclose. |
| Andrea Falini | No disclosure on file |
| Gabriele Mora, MD | Dr. Mora has nothing to disclose. |
| Giuseppe Magnani | Giuseppe Magnani has nothing to disclose. |
| Sarah J. Rathman, DO | Mrs. Inbornone has nothing to disclose. |
| Massimiliano Copetti | No disclosure on file |
| Jonathan D. Glass, MD | Dr. Glass has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Glass has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Apic Bio. Dr. Glass has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CIRM. Dr. Glass has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Bryan Cave Leighton Paisner. The institution of Dr. Glass has received research support from NIH. The institution of Dr. Glass has received research support from ALS Assoiciation. The institution of Dr. Glass has received research support from Muscular Dystrophy Assoication. |
| Neill R. Graff-Radford, MD, FAAN | The institution of Dr. Graff-Radford has received research support from Biogen. The institution of Dr. Graff-Radford has received research support from Lilly. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Biogen. Dr. Graff-Radford has received publishing royalties from a publication relating to health care. |
| M. Antonietta Volonte, MD | Dr. Volonte has nothing to disclose. |
| Francesca Caso, MD | Dr. Caso has nothing to disclose. |
| Cristina Moglia | Cristina Moglia has nothing to disclose. |
| Saila Upadhyayula, MD | Dr. Upadhyayula has nothing to disclose. |
| Nereo Bresolin, DR | No disclosure on file |
| Bradley F. Boeve, MD, FAAN | Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care. |
| Ronald C. Petersen, MD, PhD, FAAN | Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities. |
| Kevin B. Boylan, MD | No disclosure on file |
| Mohammed S. Sanjak, PhD | No disclosure on file |
| Keith A. Josephs, Jr., MD, FAAN | Dr. Josephs has nothing to disclose. |
| Umberto Manera, MD | Dr. Manera has nothing to disclose. |
| Jeffrey D. Rothstein, MD, PhD | Dr. Rothstein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Expansion Therapeutics. Dr. Rothstein has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal Clinical Investigation. The institution of Dr. Rothstein has received research support from ALSA. The institution of Dr. Rothstein has received research support from MDA. The institution of Dr. Rothstein has received research support from F Prime. The institution of Dr. Rothstein has received research support from Target ALS. The institution of Dr. Rothstein has received research support from Chan Zuckerberg Initiative. The institution of Dr. Rothstein has received research support from Dept of Defense. Dr. Rothstein has received intellectual property interests from a discovery or technology relating to health care. |
| Priscilla C. Russo | No disclosure on file |
| Ryan M. Seals | No disclosure on file |
| Marc Weisskopf, PhD | Dr. Weisskopf has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer. The institution of Dr. Weisskopf has received research support from Biogen. The institution of Dr. Weisskopf has received research support from NIH. |
| Federica Agosta | Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC. |
| Urvi G. Desai, MD, FAAN | Dr. Desai has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Desai has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Fulcrum. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Argenx. |
| Rosa Rademakers, PhD | Rosa Rademakers, PhD has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Mayo Clinic. Rosa Rademakers, PhD has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arkuda Therapeutics. Rosa Rademakers, PhD has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Alzheimer Fondation. Rosa Rademakers, PhD has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Kisick Family Foundation (FTD grant program). The institution of Rosa Rademakers, PhD has received research support from NIH. The institution of Rosa Rademakers, PhD has received research support from DOD. The institution of Rosa Rademakers, PhD has received research support from Flanders Institute for Biotechnology (VIB). The institution of Rosa Rademakers, PhD has received research support from Flanders Funds for Scientific Research. |
| Joseph E. Parisi, MD | Dr. Parisi has nothing to disclose. |
| Matthew C. Kiernan, MBBS, PhD, FRACP | The institution of Prof. Kiernan has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for British Medical Journal Publishers (UK). |
| Amber L. Ward | No disclosure on file |
| Matthew Baker | No disclosure on file |
| Elena Bravver, MD | No disclosure on file |
| David B. Goldstein, PhD | No disclosure on file |
| Elizabeth T. Cirulli, PhD | No disclosure on file |
| Con Yiannikas, MBBS | Dr. Yiannikas has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. |
| Nimeshan Geevasinga, MD, PhD | No disclosure on file |
| Giacomo Comi | Giacomo Comi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Giacomo Comi has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. |
| Kazuko Matsuda, MD | No disclosure on file |
| Joanna Dojillo, MSc | No disclosure on file |
| Antonio Canosa | Antonio Canosa has nothing to disclose. |
| Johnni Hansen, PhD | Dr. Hansen has nothing to disclose. |
| Edoardo G. Spinelli, MD | Dr. Spinelli has nothing to disclose. |
| Giancarlo Comi, MD | Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Aspen Healthcare. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Sanofi. Dr. Comi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Rewind. |
| Letizia Mazzini | No disclosure on file |
| Ole Gredal | No disclosure on file |
| Sandra D'Alfonso | No disclosure on file |
| Elisa Canu | The institution of Elisa Canu has received research support from Italian Ministry of Health . |
| Sandro Iannaccone | No disclosure on file |
| Christina N. Fournier, MD, MSc | Dr. Fournier has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Fournier has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roon. Dr. Fournier has received personal compensation in the range of $500-$4,999 for serving as a Consultant for QurAlis. Dr. Fournier has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Journals. The institution of Dr. Fournier has received research support from Veterans Affairs. The institution of Dr. Fournier has received research support from Department of Defense. The institution of Dr. Fournier has received research support from Amylyx. The institution of Dr. Fournier has received research support from Biogen. The institution of Dr. Fournier has received research support from MT Pharma. The institution of Dr. Fournier has received research support from Columbia University. The institution of Dr. Fournier has received research support from Denali. |
| Mohamed M. Alwan, MD | No disclosure on file |
| Richard S. Bedlack, MD, PhD, FAAN | Dr. Bedlack has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Guidepoint Global. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for New Biotic. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Woolsey Pharma. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amylyx. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ITF Pharma. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Mitsubishi Tanabe America. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orphazyme. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AB Scicence. Dr. Bedlack has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for ALS Association. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Adept Field Solutions. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Apellis. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Black Swan. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clarivate. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clearview. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clean. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CM Group. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Corcept. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cytokinetics. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Health Advances. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MT Pharma America. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MJH Healthcare. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Maple Health Care. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for National Association of Managed Care Physicians. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Projects in Knowledge. Dr. Bedlack has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Shinkei Pharma. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Webb MD/Medscape. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Bedlack has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Brainstorm Cell. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mallinkrodt. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion . Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurosense. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapeutics. Dr. Bedlack has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amylyx. Dr. Bedlack has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for GenieUS. The institution of Dr. Bedlack has received research support from Cytokinetics. The institution of Dr. Bedlack has received research support from Orion. The institution of Dr. Bedlack has received research support from Ultragenyx. The institution of Dr. Bedlack has received research support from MediciNova. The institution of Dr. Bedlack has received research support from Healey Center. Dr. Bedlack has received publishing royalties from a publication relating to health care. |